No recent analyst price targets found for HLTRF.
Latest News for HLTRF
HLS Therapeutics Q1 Earnings Call Highlights
HLS Therapeutics TSE: HLS reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company's newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for HLTRF.
Senate Trading
No Senate trades found for HLTRF.
U.S. House Trading
No House trades found for HLTRF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.